• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

巨噬细胞上B7-H1的阻断通过增强干扰素-γ诱导的一氧化氮生成来抑制CD4+ T细胞增殖。

Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production.

作者信息

Yamazaki Tomohide, Akiba Hisaya, Koyanagi Akemi, Azuma Miyuki, Yagita Hideo, Okumura Ko

机构信息

Department of Immunology, Juntendo University School of Medicine, Hongo, Tokyo, Japan.

出版信息

J Immunol. 2005 Aug 1;175(3):1586-92. doi: 10.4049/jimmunol.175.3.1586.

DOI:10.4049/jimmunol.175.3.1586
PMID:16034097
Abstract

PD-1 is an immunoinhibitory receptor that belongs to the CD28/CTLA-4 family. B7-H1 (PD-L1) and B7-DC (PD-L2), which belong to the B7 family, have been identified as ligands for PD-1. Paradoxically, it has been reported that both B7-H1 and B7-DC co-stimulate or inhibit T cell proliferation and cytokine production. To determine the role of B7-H1 and B7-DC in T cell-APC interactions, we examined the contribution of B7-H1 and B7-DC to CD4+ T cell activation by B cells, dendritic cells, and macrophages using anti-B7-H1, anti-B7-DC, and anti-PD-1 blocking mAbs. Anti-B7-H1 mAb and its Fab markedly inhibited the proliferation of anti-CD3-stimulated naive CD4+ T cells, but enhanced IL-2 and IFN-gamma production in the presence of macrophages. The inhibition of T cell proliferation by anti-B7-H1 mAb was abolished by neutralizing anti-IFN-gamma mAb. Coculture of CD4+ T cells and macrophages from IFN-gamma-deficient or wild-type mice showed that CD4+ T cell-derived IFN-gamma was mainly responsible for the inhibition of CD4+ T cell proliferation. Anti-B7-H1 mAb induced IFN-gamma-mediated production of NO by macrophages, and inducible NO synthase inhibitors abrogated the inhibition of CD4+ T cell proliferation by anti-B7-H1 mAb. These results indicated that the inhibition of T cell proliferation by anti-B7-H1 mAb was due to enhanced IFN-gamma production, which augmented NO production by macrophages, suggesting a critical role for B7-H1 on macrophages in regulating IFN-gamma production by naive CD4+ T cells and, hence, NO production by macrophages.

摘要

PD-1是一种免疫抑制性受体,属于CD28/CTLA-4家族。已确定属于B7家族的B7-H1(PD-L1)和B7-DC(PD-L2)是PD-1的配体。矛盾的是,有报道称B7-H1和B7-DC均可共刺激或抑制T细胞增殖及细胞因子产生。为确定B7-H1和B7-DC在T细胞与抗原呈递细胞(APC)相互作用中的作用,我们使用抗B7-H1、抗B7-DC和抗PD-1阻断单克隆抗体,研究了B7-H1和B7-DC对B细胞、树突状细胞和巨噬细胞激活CD4+T细胞的作用。抗B7-H1单克隆抗体及其Fab片段显著抑制抗CD3刺激的初始CD4+T细胞增殖,但在巨噬细胞存在的情况下增强了IL-2和IFN-γ的产生。抗IFN-γ单克隆抗体可消除抗B7-H1单克隆抗体对T细胞增殖的抑制作用。来自IFN-γ缺陷或野生型小鼠的CD4+T细胞与巨噬细胞共培养显示,CD4+T细胞来源的IFN-γ主要负责抑制CD4+T细胞增殖。抗B7-H1单克隆抗体诱导巨噬细胞产生IFN-γ介导的NO,诱导型NO合酶抑制剂可消除抗B7-H1单克隆抗体对CD4+T细胞增殖的抑制作用。这些结果表明,抗B7-H1单克隆抗体对T细胞增殖的抑制作用是由于IFN-γ产生增加,进而增强了巨噬细胞的NO产生,提示巨噬细胞上的B7-H1在调节初始CD4+T细胞的IFN-γ产生以及巨噬细胞的NO产生中起关键作用。

相似文献

1
Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production.巨噬细胞上B7-H1的阻断通过增强干扰素-γ诱导的一氧化氮生成来抑制CD4+ T细胞增殖。
J Immunol. 2005 Aug 1;175(3):1586-92. doi: 10.4049/jimmunol.175.3.1586.
2
Expression of programmed death 1 ligands by murine T cells and APC.小鼠T细胞和抗原呈递细胞程序性死亡1配体的表达
J Immunol. 2002 Nov 15;169(10):5538-45. doi: 10.4049/jimmunol.169.10.5538.
3
B7-DC regulates asthmatic response by an IFN-gamma-dependent mechanism.B7-DC 通过一种依赖干扰素-γ 的机制调节哮喘反应。
J Immunol. 2004 Feb 15;172(4):2530-41. doi: 10.4049/jimmunol.172.4.2530.
4
Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model.在小鼠胰腺癌模型中,阻断B7-H1或B7-DC可诱导抗肿瘤效应。
Int J Oncol. 2009 Oct;35(4):741-9. doi: 10.3892/ijo_00000387.
5
Blockade of B7-H1 suppresses the development of chronic intestinal inflammation.阻断B7-H1可抑制慢性肠道炎症的发展。
J Immunol. 2003 Oct 15;171(8):4156-63. doi: 10.4049/jimmunol.171.8.4156.
6
Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.体内CD4和CD8 T细胞介导的同种异体免疫反应中负性T细胞共刺激途径的作用分析
J Immunol. 2005 Jun 1;174(11):6648-56. doi: 10.4049/jimmunol.174.11.6648.
7
Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.阻断树突状细胞上的程序性死亡-1配体可增强T细胞活化和细胞因子产生。
J Immunol. 2003 Feb 1;170(3):1257-66. doi: 10.4049/jimmunol.170.3.1257.
8
Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells.人类CD4+ T细胞对B7-1/B7-2的结扎触发树突状细胞中的吲哚胺2,3-双加氧酶活性。
J Immunol. 2004 Apr 1;172(7):4100-10. doi: 10.4049/jimmunol.172.7.4100.
9
Blockade of endogenous B7-H1 suppresses antibacterial protection after primary Listeria monocytogenes infection.内源性B7-H1的阻断会抑制原发性单核细胞增多性李斯特菌感染后的抗菌保护作用。
Immunology. 2008 Jan;123(1):90-9. doi: 10.1111/j.1365-2567.2007.02708.x. Epub 2007 Oct 25.
10
B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy.树突状细胞上的B7-H1(程序性死亡-1配体)参与T细胞无反应性的诱导和维持。
J Immunol. 2003 Apr 1;170(7):3637-44. doi: 10.4049/jimmunol.170.7.3637.

引用本文的文献

1
ANV600 is a novel PD-1 targeted IL-2Rβγ agonist that selectively expands tumor antigen-specific T cells and potentiates PD-1 checkpoint inhibitor therapy.ANV600是一种新型的靶向程序性死亡受体1(PD-1)的白细胞介素-2受体βγ激动剂,可选择性扩增肿瘤抗原特异性T细胞,并增强程序性死亡受体1(PD-1)检查点抑制剂疗法的效果。
J Immunother Cancer. 2025 Jul 15;13(7):e011905. doi: 10.1136/jitc-2025-011905.
2
Common inherited loss-of-function mutations in the innate sensor NOD2 contribute to exceptional immune response to cancer immunotherapy.先天性传感器NOD2中常见的遗传性功能丧失突变有助于对癌症免疫疗法产生特殊的免疫反应。
Proc Natl Acad Sci U S A. 2025 Jul 15;122(28):e2314258122. doi: 10.1073/pnas.2314258122. Epub 2025 Jul 7.
3
T Cell Resistance: On the Mechanisms of T Cell Non-activation.
T细胞抗性:关于T细胞未激活的机制
Immune Netw. 2024 Dec 19;24(6):e42. doi: 10.4110/in.2024.24.e42. eCollection 2024 Dec.
4
Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors.恶性实体瘤中检查点抑制剂的预测生物标志物和耐药机制。
Int J Mol Sci. 2024 Sep 6;25(17):9659. doi: 10.3390/ijms25179659.
5
Machine Learning-Directed Conversion of Glioblastoma Cells to Dendritic Cell-Like Antigen-Presenting Cells as Cancer Immunotherapy.机器学习引导的胶质母细胞瘤细胞向树突状细胞样抗原呈递细胞的转化作为癌症免疫疗法
Cancer Immunol Res. 2024 Oct 1;12(10):1340-1360. doi: 10.1158/2326-6066.CIR-23-0721.
6
Programmed death-ligand 1 (PD-L1) expression in cervical intraepithelial neoplasia and cervical squamous cell carcinoma of HIV-infected and non-infected patients.程序性死亡配体 1(PD-L1)在感染和未感染 HIV 的宫颈上皮内瘤变和宫颈鳞状细胞癌中的表达。
Virchows Arch. 2024 Mar;484(3):507-516. doi: 10.1007/s00428-023-03580-z. Epub 2023 Jun 21.
7
Inhibition of interferon-gamma-stimulated melanoma progression by targeting neuronal nitric oxide synthase (nNOS).靶向神经元型一氧化氮合酶(nNOS)抑制干扰素-γ刺激的黑色素瘤进展。
Sci Rep. 2022 Feb 1;12(1):1701. doi: 10.1038/s41598-022-05394-6.
8
Depleting Tumor Cells Expressing Immune Checkpoint Ligands-A New Approach to Combat Cancer.耗竭表达免疫检查点配体的肿瘤细胞——一种治疗癌症的新方法。
Cells. 2021 Apr 12;10(4):872. doi: 10.3390/cells10040872.
9
Associations of PD-L1, PD-L2, and HLA class I expression with responses to immunotherapy in patients with advanced sarcoma: post hoc analysis of a phase 1/2 trial.晚期肉瘤患者免疫治疗反应与 PD-L1、PD-L2 和 HLA Ⅰ类表达的相关性:一项 1/2 期试验的事后分析。
Clin Transl Oncol. 2021 Aug;23(8):1620-1629. doi: 10.1007/s12094-021-02559-z. Epub 2021 Feb 26.
10
Natural Killer T-Cell Agonist α-Galactosylceramide and PD-1 Blockade Synergize to Reduce Tumor Development in a Preclinical Model of Colon Cancer.天然杀伤 T 细胞激动剂 α-半乳糖神经酰胺与 PD-1 阻断协同作用可减少结肠癌临床前模型中的肿瘤发生。
Front Immunol. 2020 Oct 20;11:581301. doi: 10.3389/fimmu.2020.581301. eCollection 2020.